Cipher Pharmaceuticals has presented the safety and efficacy results from a Phase III safety study of CIP-Isotretinoin, used for the treatment of severe nodular acne.

The randomised, double-blinded and non-inferiority trial, which included 925 patients, showed that the drug met the co-primary endpoints of a total change in lesion counts and 90% clearing at the end of 20 weeks of treatment.

The results also demonstrated safety, efficacy and pharmacokinetic profile of CIP-Isotretinoin.

Side effects observed include dry skin, dry lips, eye disorders, ear disorders, musculoskeletal, vascular disorders, cardiac disorders and gastrointestinal disorders.